$Esperion Therapeutics (ESPR.US)$tipranks.com/ne...
Esperion should be trading well above $5 , it's $2.41 & had high last week of $3.97.
From StockTwits : Canyon_Partners15m$ESPR$NAMSDrug no hs-CRP reduction, unlike ESPERION THERAPEUTICS NEXLIZET & NEXLETOL that drop hs-CRP levels by 25%. ESPR should be trading above$AMClevels & so many other stocks. My$BBAI&$SOUNhave done better than ESPR yet ESPR has more earnings power by selling the only st...

$Plug Power (PLUG.US)$ Oct. 29, 2024, 05:42 AM
In a report released today, Kashy Harrison from Piper Sandler maintained a Sell rating on Plug Power (PLUG – Research Report), with a price target of $1.60. The company’s shares closed yesterday at $2.24.

$Esperion Therapeutics (ESPR.US)$ The recent analyst note from Jeff sugest Esperion might sell the entire rights for Bempedoic Acid. Fair valuation on the rights would be above $1.5 billion, based on future milestones $900 million, future royalties & patents, the current formulation patent has exp date Dec 2031. The potential yearly sales in the U.S could reach $4 billion by 2027.
Esperion could also partner in the U.S .
Keep an...

$Plug Power (PLUG.US)$ currently at $2.12 PLUG is trading below fair value. Book value is $3.79 & Growth ability is tremendous. This energy sector play is must have in the speculative part of your portfolio. Analysts need to get behind this company.